Increased Platelet Production [PE] - N0000175970

Name: Table of NDC products with increased platelet production
Creator: U.S. Food & Drug Administration
License: https://creativecommons.org/licenses/by-nc-sa/4.0/

Pharmacologic Class Information

Pharmacologic Code	N0000175970
Pharmacologic Name	Increased Platelet Production
Pharmacologic Concept	Physiologic Effects - [PE]
Pharmacologic Concept Description	This concept refers to the tissue, organ, or organ system effects of drug generic ingredients, organized into an organ system classification hierarchy, beneath the "Physiological Effects [PE]" concept.

NDC Products with Increased Platelet Production

The table contains 9 products whose active ingredient are classified under the same pharmacologic class Increased Platelet Production [PE].

NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
0078-0684	Promacta	Non-Proprietary Name: Eltrombopag Olamine	Tablet, Film Coated	Oral	Novartis Pharmaceuticals Corporation	ACTIVE
0078-0685	Promacta	Non-Proprietary Name: Eltrombopag Olamine	Tablet, Film Coated	Oral	Novartis Pharmaceuticals Corporation	ACTIVE
0078-0686	Promacta	Non-Proprietary Name: Eltrombopag Olamine	Tablet, Film Coated	Oral	Novartis Pharmaceuticals Corporation	ACTIVE
0078-0687	Promacta	Non-Proprietary Name: Eltrombopag Olamine	Tablet, Film Coated	Oral	Novartis Pharmaceuticals Corporation	ACTIVE
0078-0697	Promacta	Non-Proprietary Name: Eltrombopag Olamine	Powder, For Suspension	Oral	Novartis Pharmaceuticals Corporation	ACTIVE
0078-0972	Promacta	Non-Proprietary Name: Eltrombopag Olamine	Powder, For Suspension	Oral	Novartis Pharmaceuticals Corporation	ACTIVE
55513-221	Nplate	Non-Proprietary Name: Romiplostim	Injection, Powder, Lyophilized, For Solution	Subcutaneous	Amgen Inc	ACTIVE
55513-222	Nplate	Non-Proprietary Name: Romiplostim	Injection, Powder, Lyophilized, For Solution	Subcutaneous	Amgen Inc	ACTIVE
55513-223	Nplate	Non-Proprietary Name: Romiplostim	Injection, Powder, Lyophilized, For Solution	Subcutaneous	Amgen Inc	ACTIVE